Company Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases.
In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency.
Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No.
3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
| Country | United States |
| IPO Date | Jun 16, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 525 |
| CEO | Dr. Christopher R. Anzalone Ph.D. |
Contact Details
Address: 177 E Colorado Blvd, Suite 700 Pasadena, California 91105 United States | |
| Phone | 626-696-4702 |
| Website | arrowheadpharma.com |
Stock Details
| Ticker Symbol | ARWR |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0000879407 |
| CUSIP Number | 04280A100 |
| ISIN Number | US04280A1007 |
| Employer ID | 46-0408024 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christopher R. Anzalone Ph.D. | Chief Executive Officer, President and Director |
| Kenneth A. Myszkowski | Chief Financial Officer |
| Patrick O'Brien J.D., PharmD | Chief Operating Officer, General Counsel and Secretary |
| Dr. James C. Hamilton M.D., MBA | Chief of Discovery and Translational Medicine |
| Dr. Mark M. Davis Ph.D. | Founder and Founder and Director of Insert Therapeutics Inc & Calando |
| Dr. Vincent Anzalone CFA | Head of Investor Relations and Vice President |
| Howard Lovy | Director of Communications |
| Dr. Bruce D. Given M.D. | Chief Medical Scientist |
| Dr. Mark Seefeld | Head of Toxicology and Vice President |
| Tracie Oliver | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2024 | 144 | Filing |
| Apr 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Apr 1, 2024 | 144 | Filing |
| Mar 19, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 8-K/A | [Amend] Current report |
| Mar 6, 2024 | 144 | Filing |
| Feb 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Feb 22, 2024 | 8-K | Current Report |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |